Krystal Biotech
KRYS
183 hedge funds and large institutions have $2.71B invested in Krystal Biotech in 2023 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 60 increasing their positions, 63 reducing their positions, and 15 closing their positions.
167% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 15
61% more capital invested
Capital invested by funds: $1.68B → $2.71B (+$1.03B)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
30% more call options, than puts
Call options by funds: $26M | Put options by funds: $20M
14% more funds holding
Funds holding: 160 → 183 (+23)
7.92% more ownership
Funds ownership: 81.44% → 89.36% (+7.9%)
5% less repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 63
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$82.8M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$66.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$51.5M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$49.5M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$32.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$25M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$20.7M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$16.9M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$13.6M |
| 5 |
State Street
Boston,
Massachusetts
|
-$12.5M |
KRYS Hedge Fund Activity: Q2 2023 in Review
183 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q2 2023, worth a combined $2.71B — up 61% from $1.68B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new KRYS positions and 15 closed out — a net gain of 25 holders — while 60 added to existing stakes and 63 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $82.8M. The largest seller was Deerfield Management, exiting entirely with an estimated $25M sold.
- 183 institutional investors held Krystal Biotech (KRYS) as of Q2 2023, up from 160 in Q1 2023.
- Funds reported $2.71B of Krystal Biotech stock for Q2 2023, up 61% quarter-over-quarter.
- 40 funds opened new Krystal Biotech positions in Q2 2023 and 15 closed out, a net change of +25 holders.
- The largest Krystal Biotech buyer in Q2 2023 was Avoro Capital Advisors, an estimated $82.8M added.
- The largest Krystal Biotech seller in Q2 2023 was Deerfield Management, an estimated $25M sold.
Based on aggregated 13F filings for Q2 2023.